Table 1 Characteristics of studies on association between CD44 single nucleotide polymorphisms and cancers.

From: Associations of five polymorphisms in the CD44 gene with cancer susceptibility in Asians

Single Nucleotide Polymorphisms	Author	Year	Ethnicity	Cancers	Genotyping Method	Quality Score	Cases	Controls	Source of Controls	P for HWE in controls	Cases			Controls
Single Nucleotide Polymorphisms	Author	Year	Ethnicity	Cancers	Genotyping Method	Quality Score	Cases	Controls	Source of Controls	P for HWE in controls	AA	AB	BB	AA	AB	BB
rs13347	Yadav^a	2015	Indian	GBC	TaqMan, ARMS-PCR, PCR-RFLP	9	610	250	PB	0.62	378	201	31	162	80	8
rs13347	Wu	2015	Chinese	CRC	MALDI-TOF mass spectrometry	9	946	989	PB	0.28	416	441	89	578	348	63
rs13347	Weng	2015	Chinese	TCC	TaqMan	8	275	275	HB	0.15	138	111	26	143	117	15
rs13347	Liu	2015	Chinese	NSCLC	Taqman	8	234	468	HB	0.82	179	51	4	337	121	10
rs13347	Sharma^a	2014	Indian	GBC	TaqMan, PCR-RFLP	9	405	200	PB	0.57	293	104	8	154	42	4
rs13347	Lou	2014	Chinese	NPC	ABI 3730xl sequencing platform	8	287	507	HB	0.91	104	126	42	288	174	27
rs13347	Chou-1^b	2014	Chinese	OSCC	TaqMan	7	599	561	HB	0.92	287	262	50	295	223	43
rs13347	Chou-2^b	2014	Chinese	HCC	TaqMan	7	203	561	HB	0.92	110	72	21	295	223	43
rs13347	Xiao	2013	Chinese	NPC	MALDI-TOF mass spectrometry	9	906	943	PB	0.64	386	418	102	606	297	40
rs13347	Wu	2013	Chinese	AML	MALDI-TOF mass spectrometry	9	421	461	PB	0.34	163	196	62	254	171	36
rs13347	Tulsyan	2013	Indian	BC	ABI 7500 Real Time PCR system	8	258	241	HB	0.58	191	60	7	178	57	6
rs13347	Jiang	2012	Chinese	BC	MALDI-TOF mass spectrometry	9	1049	1157	PB	0.84	451	484	114	654	430	73
rs11821102	Wu	2015	Chinese	CRC	MALDI-TOF mass spectrometry	9	946	989	PB	<0.001	815	119	12	843	131	15
rs11821102	Weng	2015	Chinese	TCC	TaqMan	8	275	275	HB	0.92	234	39	2	222	50	3
rs11821102	Lou	2014	Chinese	NPC	ABI 3730xl sequencing platform	8	287	507	HB	0.35	252	27	1	439	54	3
rs11821102	Chou-1^b	2014	Chinese	OSCC	TaqMan	7	599	561	HB	0.28	531	63	5	481	75	5
rs11821102	Chou-2^b	2014	Chinese	HCC	TaqMan	7	203	561	HB	0.28	173	29	1	481	75	5
rs11821102	Xiao	2013	Chinese	NPC	MALDI-TOF mass spectrometry	9	906	943	PB	0.14	796	100	10	805	129	9
rs11821102	Wu	2013	Chinese	AML	MALDI-TOF mass spectrometry	9	421	461	PB	0.28	370	50	1	398	59	4
rs11821102	Jiang	2012	Chinese	BC	MALDI-TOF mass spectrometry	9	1049	1157	PB	0.22	912	125	12	997	151	9
rs10836347	Wu	2015	Chinese	CRC	MALDI-TOF mass spectrometry	9	946	989	PB	0.10	821	120	5	851	129	9
rs10836347	Lou	2014	Chinese	NPC	ABI 3730xl sequencing platform	8	287	507	HB	0.85	249	27	2	438	55	2
rs10836347	Chou-1^b	2014	Chinese	OSCC	TaqMan	7	599	561	HB	0.15	522	73	4	487	69	5
rs10836347	Chou-2^b	2014	Chinese	HCC	TaqMan	7	203	561	HB	0.15	180	23	0	487	69	5
rs10836347	Xiao	2013	Chinese	NPC	MALDI-TOF mass spectrometry	9	906	943	PB	0.31	785	118	3	792	147	4
rs10836347	Wu	2013	Chinese	AML	MALDI-TOF mass spectrometry	9	421	461	PB	0.93	364	55	2	404	55	2
rs10836347	Jiang	2012	Chinese	BC	MALDI-TOF mass spectrometry	9	1049	1157	PB	0.97	906	139	4	995	156	6
rs713330	Weng	2015	Chinese	TCC	TaqMan	8	275	275	HB	0.87	231	42	2	223	49	3
rs713330	Chou-1^b	2014	Chinese	OSCC	TaqMan	7	599	561	HB	0.09	507	88	4	467	86	8
rs713330	Chou-2^b	2014	Chinese	HCC	TaqMan	7	203	561	HB	0.09	167	36	0	467	86	8
rs713330	Xiao	2013	Chinese	NPC	MALDI-TOF mass spectrometry	9	906	943	PB	0.74	732	164	10	751	180	12
rs713330	Wu	2013	Chinese	AML	MALDI-TOF mass spectrometry	9	421	461	PB	0.39	341	74	6	371	87	3
rs713330	Jiang	2012	Chinese	BC	MALDI-TOF mass spectrometry	9	1049	1157	PB	0.39	865	172	12	950	194	13
rs1425802	Weng	2015	Chinese	TCC	TaqMan	8	275	275	HB	0.001	105	121	49	99	109	67
rs1425802	Chou-1^b	2014	Chinese	OSCC	TaqMan	7	599	561	HB	< 0.001	197	249	153	194	235	132
rs1425802	Chou-2^b	2014	Chinese	HCC	TaqMan	7	203	561	HB	< 0.001	70	75	58	194	235	132
rs1425802	Xiao	2013	Chinese	NPC	MALDI-TOF mass spectrometry	9	906	943	PB	0.11	270	450	186	299	442	202
rs1425802	Wu	2013	Chinese	AML	MALDI-TOF mass spectrometry	9	421	461	PB	0.08	126	204	91	122	248	91
rs1425802	Jiang	2012	Chinese	BC	MALDI-TOF mass spectrometry	9	1049	1157	PB	0.55	316	513	220	353	563	241

PB: population-based. HB: hospital-based. PCR: polymerase chain reaction. RFLP: restriction fragment length polymorphism. ARMS: amplification refractory mutation system. HWE: Hardy-Weinberg equilibrium. GBC: gallbladder cancer. CRC: colorectal cancer. TCC: transitional cell carcinoma of urinary bladder. NSCLC: non-small cell lung cancer. NPC: nasopharyngeal carcinoma. OSCC: oral squamous cell carcinoma. HCC: hepatocellular carcinoma. AML: acute myeloid leukemia. BC: breast cancer.
^aContaining repeated data.
^bContaining the same population of controls.

Back to article page

Table 1 Characteristics of studies on association between CD44 single nucleotide polymorphisms and cancers.

Search

Quick links